Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340569 | 0.87 | SIGMAR1 (0.46) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL3476725 | 0.79 | CYP2D6 (0.53) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2719462 | 0.76 | CYP2D6 (0.50) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL447453 | 0.76 | SIGMAR1 (0.44) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2719458 | 0.74 | ALDH1A1 (0.46) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL2488884 | 0.73 | SLC6A2 (0.52) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL1730609 | 0.73 | TAAR1 (0.50) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| Benzylamine SCHEMBL5533155 | 0.70 | LOXL2 (0.42) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| SCHEMBL37760 | 0.70 | SIGMAR1 (0.44) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 | |
| Benzylamine SCHEMBL28373205 | 0.70 | SIGMAR1 (0.44) | SIGMAR1SLC6A2TAAR1MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975091-B2 | Composition for enhancing protein strength | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2024-05-07 | — | — | US | claimed |
| US-10196349-B2 | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-02-05 | — | — | US | claimed |
| US-20120015002-A1 | ANTIMICROBIAL COATINGS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-01-19 | — | — | US | claimed |
| US-20070286994-A1 | DURABLE ANTIREFLECTIVE FILM | 3M INNOVATIVE PROPERTIES COMPANY | 2007-12-13 | — | — | US | claimed |
| US-10322082-B2 | Topical antiviral compositions and methods of using the same | NOVAN, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-9919072-B2 | Wound dressings, methods of using the same and methods of forming the same | NOVAN, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180008533-A1 | TOPICAL ANTIVIRAL COMPOSITIONS AND METHODS OF USING THE SAME | LIGAND PHARMACEUTICALS INCORPORATED | 2018-01-11 | — | — | US | disclosed |
| US-9737561-B2 | Topical gels and methods of using the same | NOVAN, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170056437-A1 | TOPICAL GELS AND METHODS OF USING THE SAME | LIGAND PHARMACEUTICALS INCORPORATED | 2017-03-02 | — | — | US | disclosed |
| US-9526738-B2 | Topical gels and methods of using the same | NOVAN, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2539394-B1 | RUBBER COMPOSITIONS INCLUDING SILICEOUS FILLERS | BRIDGESTONE CORP (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-8591876-B2 | Methods of decreasing sebum production in the skin | NOVAN, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20100239776-A1 | METHOD FOR PRODUCING PLASTIC LENS | HOYA CORPORATION (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100232021-A1 | DURABLE ANTIREFLECTIVE FILM | 3M INNOVATIVE PROPERTIES COMPANY | 2010-09-16 | — | — | US | disclosed |
| US-7537828-B2 | Low refractive index composition comprising fluoropolyether urethane compound | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080240479-A1 | HYDROPHOBIC AND OLEOPHOBIC COATING AND METHOD FOR PREPARING THE SAME | SONIC INNOVATIONS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20070286994-A1 | DURABLE ANTIREFLECTIVE FILM | 3M INNOVATIVE PROPERTIES COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070286992-A1 | LOW REFRACTIVE INDEX COMPOSITION COMPRISING FLUOROPOLYETHER URETHANE COMPOUND | 3M INNOVATION PROPERTIES COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070285778-A1 | OPTICAL FILMS COMPRISING HIGH REFRACTIVE INDEX AND ANTIREFLECTIVE COATINGS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070285779-A1 | OPTICAL FILMS COMPRISING HIGH REFRACTIVE INDEX AND ANTIREFLECTIVE COATINGS | 3M INNOVATIVE PROPERTIES COMPANY | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975091-B2 | Composition for enhancing protein strength | CUTA, S100A4, S100A8 | SIGMAR1 2831/4885SLC6A2 4119/4885TAAR1 1760/4885 |
| US-20120015002-A1 | ANTIMICROBIAL COATINGS | ARG1, CAPG, CLSPN | SIGMAR1 673/4885SLC6A2 3196/4885TAAR1 4128/4885 |
| US-10196349-B2 | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures | NOS2, NOS3, NOS1 | SIGMAR1 871/4885SLC6A2 532/4885TAAR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.